Clinical Trial: ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524257) titled 'ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC' on March 26.

Brief Summary: This Phase 3 study will enroll adults with untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable mutations to test whether adding nogapendekin alfa inbakicept (an IL-15 receptor agonist, NAI) to standard first-line chemoimmunotherapy (pembrolizumab plus platinum-based chemotherapy ± histology-specific agent) improves how long patients live without their cancer worsening (progression-free survival). Participants are randomized 1:1 to receive standard chemoimmunothe...